Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Adjuvant Therapy in dMMR/MSI-H Colon Cancer
NCT05231850Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in colon cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05231850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231850.